GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Cyclically Adjusted PB Ratio

Xbrane Biopharma AB (STU:7XB) Cyclically Adjusted PB Ratio : 0.10 (As of May. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB Cyclically Adjusted PB Ratio?

As of today (2024-05-27), Xbrane Biopharma AB's current share price is €0.0168. Xbrane Biopharma AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €0.17. Xbrane Biopharma AB's Cyclically Adjusted PB Ratio for today is 0.10.

The historical rank and industry rank for Xbrane Biopharma AB's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:7XB' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.11   Med: 0.13   Max: 0.2
Current: 0.13

During the past years, Xbrane Biopharma AB's highest Cyclically Adjusted PB Ratio was 0.20. The lowest was 0.11. And the median was 0.13.

STU:7XB's Cyclically Adjusted PB Ratio is ranked better than
85.76% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs STU:7XB: 0.13

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Xbrane Biopharma AB's adjusted book value per share data for the three months ended in Mar. 2024 was €0.023. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.17 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Xbrane Biopharma AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Xbrane Biopharma AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Cyclically Adjusted PB Ratio Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.16

Competitive Comparison of Xbrane Biopharma AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Xbrane Biopharma AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Cyclically Adjusted PB Ratio falls into.



Xbrane Biopharma AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Xbrane Biopharma AB's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.0168/0.17
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xbrane Biopharma AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Xbrane Biopharma AB's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.023/132.2054*132.2054
=0.023

Current CPI (Mar. 2024) = 132.2054.

Xbrane Biopharma AB Quarterly Data

Book Value per Share CPI Adj_Book
201312 0.047 100.541 0.062
201409 0.000 100.161 0.000
201412 0.032 100.225 0.042
201503 0.000 99.950 0.000
201506 0.000 99.995 0.000
201509 0.287 100.228 0.379
201512 -0.031 100.276 -0.041
201603 0.332 100.751 0.436
201606 0.315 101.019 0.412
201609 0.286 101.138 0.374
201612 0.265 102.022 0.343
201703 0.229 102.022 0.297
201706 0.196 102.752 0.252
201709 0.199 103.279 0.255
201712 0.161 103.793 0.205
201803 0.148 103.962 0.188
201806 0.092 104.875 0.116
201809 0.186 105.679 0.233
201812 0.137 105.912 0.171
201903 0.169 105.886 0.211
201906 0.242 106.742 0.300
201909 0.166 107.214 0.205
201912 0.112 107.766 0.137
202003 0.094 106.563 0.117
202006 0.107 107.498 0.132
202009 0.076 107.635 0.093
202012 0.129 108.296 0.157
202103 0.105 108.360 0.128
202106 0.076 108.928 0.092
202109 0.206 110.338 0.247
202112 0.190 112.486 0.223
202203 0.170 114.825 0.196
202206 0.155 118.384 0.173
202209 0.136 122.296 0.147
202212 0.159 126.365 0.166
202303 0.135 127.042 0.140
202306 0.133 129.407 0.136
202309 0.107 130.224 0.109
202312 0.058 131.912 0.058
202403 0.023 132.205 0.023

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xbrane Biopharma AB  (STU:7XB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Xbrane Biopharma AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB (STU:7XB) Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines